- Home
- NKSH vs ACHV Comparison
NKSH vs ACHV Comparison
Compare NKSH & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKSH
- ACHV
- Stock Information
- Founded
- NKSH 1891
- ACHV N/A
- Country
- NKSH United States
- ACHV Canada
- Employees
- NKSH N/A
- ACHV N/A
- Industry
- NKSH Major Banks
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- NKSH Finance
- ACHV Health Care
- Exchange
- NKSH Nasdaq
- ACHV Nasdaq
- Market Cap
- NKSH 182.9M
- ACHV 159.0M
- IPO Year
- NKSH N/A
- ACHV N/A
- Fundamental
- Price
- NKSH $31.79
- ACHV $4.25
- Analyst Decision
- NKSH
- ACHV Strong Buy
- Analyst Count
- NKSH 0
- ACHV 5
- Target Price
- NKSH N/A
- ACHV $14.80
- AVG Volume (30 Days)
- NKSH 10.8K
- ACHV 112.1K
- Earning Date
- NKSH 11-26-2024
- ACHV 11-07-2024
- Dividend Yield
- NKSH 4.75%
- ACHV N/A
- EPS Growth
- NKSH N/A
- ACHV N/A
- EPS
- NKSH 1.44
- ACHV N/A
- Revenue
- NKSH $43,450,000.00
- ACHV N/A
- Revenue This Year
- NKSH N/A
- ACHV N/A
- Revenue Next Year
- NKSH $14.93
- ACHV N/A
- P/E Ratio
- NKSH $22.00
- ACHV N/A
- Revenue Growth
- NKSH N/A
- ACHV N/A
- 52 Week Low
- NKSH $25.18
- ACHV $3.03
- 52 Week High
- NKSH $37.00
- ACHV $5.98
- Technical
- Relative Strength Index (RSI)
- NKSH 59.21
- ACHV 35.58
- Support Level
- NKSH $30.31
- ACHV $4.32
- Resistance Level
- NKSH $32.39
- ACHV $4.75
- Average True Range (ATR)
- NKSH 0.98
- ACHV 0.23
- MACD
- NKSH 0.14
- ACHV -0.06
- Stochastic Oscillator
- NKSH 74.89
- ACHV 9.40
About NKSH National Bankshares Inc.
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural, commercial real estate, construction for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary, National Bankshares Financial Services, Inc. The company earns its revenues from interest and fees on loans, non-interest income, and investments.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.